Impact of statin therapy on survival in epithelial ovarian cancer

Gynecologic Oncology

Volumn 111, Issue 1, 2008, Pages 102-105

  Elmore, R Geoffrey ^a   Ioffe, Yevgeniya ^a   Scoles, Daniel R ^a   Karlan, Beth Y ^a   Li, Andrew J ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Ovarian cancer; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 52249113756     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.06.007     Document Type: Article

References (27)

1. Ford E.S., Mokdad A.H., Giles W.H., and Mensah G.A. Serum total cholesterol concentrations and awareness, treatment and control of hypercholesterolemia among US adults. Circulation 107 (2003) 2185-2189
2. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
3. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
4. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent events Trial investigators. New Engl. J. Med. 335 (1996) 1001-1009
5. Ford E.S., and Giles W.H. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arteroscler. Thromb. Vasc. Biol. 20 (2000) 1052-1056
6. Herrmann J., Lerman A., Baumgart D., et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 106 (2002) 2180-2183
7. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
8. Ma J., Sehgal N.L., Ayanian J.Z., and Stafford R.S. National trends in statin use by coronary heart disease risk category. PLoS Medicine 2 (2005) 434-440
9. Graaf, M.R., Richel, D.J., van Noorden, C.J., Guchelaar, H.J., Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. 2004; 30: 609-41.
10. Pocobelli G., Newcomb P.A., Trentham-Dietz A., Titus-Ernstoff L., Hampton J.M., and Egan K.M. Statin use and risk of breast cancer. Cancer 112 (2007) 27-33
11. Bonovas S., Filioussi K., Flordellis C.S., and Sitaras N.M. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J. Clin. Oncol. 25 (2007) 3462-3468
12. Murtola T.J., Tammela T.L., Lahtela J., and Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 2226-2232
13. Freeman S.R., Drake A.L., Heilig L.F., et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J. Natl. Cancer Inst. 98 (2006) 1538-1546
14. Cauley J.A., McTiernan A., Rodabough R.J., et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. J. Natl. Cancer Inst. 98 (2006) 700-707
15. Farwell W.R., Scranton R.E., Lawler E.V., et al. The association between statins and cancer incidence in a veterans population. J. Natl. Cancer Inst. 100 (2008) 134-139
16. Platz E.A., Leitzmann M.F., Visvanathan K., et al. Statin drugs and risk of advanced prostate cancer. J. Natl. Cancer Inst. 98 (2006) 1819-1825
17. Kwan M.L., Habel L.A., Flick E.D., Quesenberry C.P., and Caan B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res. Treat. (2007) Epub
18. Shellman Y.G., Ribble D., Miller L., et al. Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma. Res. 15 (2005) 83-89
19. Koyuturk M., Ersoz M., and Altiok N. Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase. Cancer Lett. 370 (2004) 212-217
20. Girgert R., Vogt Y., Becke D., et al. Growth inhibition of neuroblastoma cells by lovastatin and l-ascorbic acid is based on different mechanisms. Cancer Lett. 137 (1999) 167-172
21. Melichar B., Ferrandina G., Verschraegen C.F., Loercher A., Abbruzzese J.L., and Freedman R.S. Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. Clin. Cancer Res. 4 (1998) 3069-3076
22. Asakage M., Tsuno N.H., Kitayama J., et al. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest. Anticancer Drugs 15 (2004) 625-632
23. Park H.J., Kong D., Irula-Arispe L., Begley U., Tang D., and Galper J.B. 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ. Res. 91 (2002) 143-150
24. Ahn K.S., Sethi G., and Aggrawal B.B. Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products. J. Immunol. 178 (2007) 2507-2516
25. Holstein S.A., and Hohl R.J. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Molec. Cancer Therapeutics 1 (2001) 141-149
26. Fromigue O., Hamidouche Z., and Marie P.J. Statin-induced inhibition of HMG-CoA reductase sensitizes human osteosarcoma cells to anticancer drugs. J. Pharmacol. Exp. Ther. (2008) epub
27. Kozar K., Kaminski R., Legat M., Kopec M., Nowis D., Skierski J.S., Koronkiewicz M., Jakóbisiak M., and Golab J. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int. J. Oncol. 24 (2004) 1149-1157